{
  "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe",
  "docSlug": "303c45082bb692ab214f73eda43168dc",
  "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 30,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 20,
  "notes": "Study methodology involves 10-week treatment on high fat/fructose/CHO diet.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/10",
  "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe",
  "deckJsonHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe.json",
  "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.35,
        "y": 0.65
      },
      "kind": "chart",
      "text": "Inflammation",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cd03d8f-48fa-4989-bdb1-95c5ee3b9110",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.35,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Plasma GLP-1",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63320ed1-af21-4c59-a379-9200fb9ed5bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Plasma ALT",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6540d0d3-8b0a-4e13-8af6-7bcb0fb3d92f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.65,
        "y": 0.65
      },
      "kind": "chart",
      "text": "Fibrosis",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd0d4e03-d824-4d6e-8850-17042400e269",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "chart",
      "text": "NAFLD Activity Score",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe4c1423-a977-498c-9b70-81092ab6c9e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Chronic treatment with DA-1241 increased plasma total GLP-1, but NOT another GPR119 agonist\nDA-1241 alleviated the progression of NASH in Ob-NASH mice on a high fat/fructose/CHO diet\nBiomarkers including CCL2 and TIMP-1 in both plasma and liver were improved accordingly",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ad9c1ad-b5b7-43f5-a44e-3e2cdc5c4a6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "NASH (Non-Alcoholic Steatohepatitis); GPR119 (G Protein-Coupled Receptor 119); GLP-1 (Glucagon-Like Peptide 1); Ob (Obese); CHO (Carbohydrate); CCL2 (C-C Motif Chemokine Ligand 2); TIMP-1 (TIMP Metallopeptidase Inhibitor 1); NAFLD (Non-Alcoholic Fatty Liver Disease). Dong-A Study Report 103143. Park H et al. 80th Meeting of the American Diabetes Association. 2020; Abstract 217-LB.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69922363-68b1-499c-95f3-a0686827c87b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "DA-1241 Attenuates NASH Progression in Obese NASH Mice (1,2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29df5c6a-b5d0-435c-8a09-baed5b3df403",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 8,
      "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents DA-1241 and DA-1726 as potential solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 20,
      "from": 9,
      "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 8,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d",
      "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential",
      "position": 1,
      "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}